Patent 11059904 was granted and assigned to Aleta Biotherapeutics on July, 2021 by the United States Patent and Trademark Office.
The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.